Aurobindo Pharma Share Price in Focus Following US FDA Inspection at API Facility

The US Food and Drug Administration has completed an inspection of Unit-VI, an API manufacturing facility of Aurobindo Pharma's wholly owned subsidiary, Apitoria Pharma Private Limited, as per an exchange filing dated August 26, 2026.  

The inspection took place over five days, from August 24 to August 28, 2026. The facility is situated at E-Bonangi Village, Parawada Mandal, in Andhra Pradesh's Anakapalli district. 

Three Observations Raised During Inspection 

The inspection ended with three observations.In its filing, Aurobindo Pharma said the three observations were procedural and added that a response would be submitted within the stipulated timeline. 

No details of the three observations were included in the filing. The company did not specify the areas covered by the observations or provide a timeline for its response beyond stating that it would meet the regulator's stipulated deadline. 

Disclosure Sent to Stock Exchanges 

The inspection related specifically to Unit-VI of Apitoria Pharma, which the company has identified as its wholly owned subsidiary. The filing did not mention any other Aurobindo Pharma or Apitoria Pharma manufacturing facility in connection with the inspection.  

Further Updates 

Aurobindo Pharma said it would keep the stock exchanges informed of any further developments, where required under applicable regulations. The company also referred to its quality and compliance standards across its manufacturing facilities.  

Read More: Honasa Consumer Share Price in Focus; Calls Off Proposed Acquisition of 58% Stake in Fluence Pharma! 

Aurobindo Pharma Share Price Performance  

As of August 28, 2026, 3:30 pm, Aurobindo Pharma share price closed at ₹1,652.00, a 0.92% increase from the previous closing price. 

Conclusion 

The US FDA inspection at Apitoria Pharma's Unit-VI API facility has concluded with three procedural observations. Aurobindo Pharma said it would respond within the stipulated timeline and report further developments to the exchanges, if required. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.   
 
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.